Intracellular expression of single-chain antibodies (scFvs) represents a promising approach for selective interference with cellular proto-oncogenes such as the epidermal growth factor receptor (EGFR). Previously, we have shown that intrabodies targeted to the lumen of the endoplasmic reticulum prevent the transit of EGFR or the related ErbB2 molecule to the cell surface, thereby inactivating their transforming potential. While intramolecular disulfide bridges important for antibody stability are correctly formed during expression in the secretory pathway, scFvs expressed in the reducing environment of the cytosol are often inactive. To overcome this problem and to generate antibody fragments that interact with the intracellular domain of human EGFR in the cytoplasm, here we have chosen a two-step approach combining classical selection of scFvs by phage display with subsequent expression in yeast. After enrichment of EGFR-specific antibody fragments from a combinatorial library by biopanning, a yeast two-hybrid screen was performed using the intracellular domain of EGFR as bait. Screening of 1.5 Â 10 5 preselected scFv plasmids under highly stringent conditions yielded 223 colonies that represented at least five independent scFv clones functional in the intracellular milieu of eukaryotic cells. Interaction of selected antibody fragments with the intracellular domain of EGFR was confirmed in GST pull-down and coimmunoprecipitation experiments. Upon cytoplasmic expression in human tumor cells, scFvs colocalized with EGFR at the plasma membrane demonstrating their functionality in vivo.
Introduction
Epidermal growth factor receptor (EGFR, ErbB) is a member of the ErbB family of receptor tyrosine kinases that also includes the closely related ErbB2 (HER2/ Neu), ErbB3 (HER3), and ErbB4 (HER4) proteins (Olayioye et al., 2000; Yarden and Sliwkowski, 2001 ). They share a common molecular architecture and consist of a glycosylated extracellular domain to which peptide ligands bind, a single transmembrane region, and a cytoplasmic domain with tyrosine kinase activity. EGFR was originally identified as a cellular proto-oncogene because of its homology with the retrovirally transduced chicken v-erbB (Downward et al., 1984) . In humans, EGFR gene amplification and protein overexpression have been found in glioblastoma and many cancers of epithelial origin, and have been linked with cancer development and progression (Gullick, 1991; Klapper et al., 2000) . This has prompted the development of therapeutic strategies aimed at targeted interference with EGFR function . One of these approaches is based on the antagonistic, partially humanized antibody C225 that blocks ligand binding to the extracellular domain of EGFR and has shown promising effects in clinical studies Shin et al., 2001) .
Experimentally, ligand-induced EGFR activation could be prevented in an autocrine fashion, and anchorage-independent growth could be inhibited upon expression of a single-chain (sc) Fv fragment of monoclonal antibody 225 directly in EGFR-transformed fibroblasts (Beerli et al., 1994a . Also, retention of EGFR or the related ErbB2 molecule (King et al., 1985) in the endoplasmic reticulum (ER) by ERresident scFvs directed to the receptors' extracellular domains severely affected receptor signaling and growth of tumor cells (Beerli et al., 1994b Deshane et al., 1994; Jannot et al., 1996) . Cell lines rendered physiologically ErbB2 negative in this way have helped to identify ErbB2 as the preferred coreceptor in the ErbB receptor signaling network (Beerli et al., 1995; Karunagaran et al., 1996; Graus-Porta et al., 1997) . Thus, antibodies expressed intracellularly (intrabodies) might be generally applicable for selective interference with signal transducing proteins or other cellular targets (Marasco, 1995 (Marasco, , 1997 Steinberger et al., 2000; Goncalves et al., 2002) .
Upon ligand-induced activation, EGFR connects extracellular signals to multiple intracellular pathways depending on adapter proteins and substrates associated with its cytoplasmic domain (Gschwind et al., 2001; Yarden and Sliwkowski, 2001) . While scFv antibodies targeted to distinct intracellular regions of EGFR might allow to interfere with these signaling pathways individually, the application of intrabodies for the analysis of cytoplasmic target proteins or protein domains is complicated by the limited functionality of scFvs in the cytosol. For stability and functional activity, antibodies are usually dependent on the formation of intradomain disulfide bonds within the variable regions of antibody heavy and light chains. These disulfide bridges are correctly assembled upon expression in the secretory pathway of cells including the ER, but they do not form in the reducing cytoplasmic environment (Biocca et al., 1995; Proba et al., 1997; Martineau et al., 1998) . This requires alternative stabilizing features of intracellular antibodies to be potent enough to promote correct folding and prevent aggregation under these conditions (Biocca et al., 1995; Proba et al., 1997; Wo¨rn and Plu¨ckthun, 1998; Cattaneo and Biocca, 1999; Zhu et al., 1999) . Only in some cases, individual antibody fragments not specifically selected for intracellular expression could be produced as functional cytoplasmic proteins (Biocca et al., 1994; Duan et al., 1994; Mhashilkar et al., 1995; Gargano and Cattaneo, 1997) . Therefore, different strategies have been suggested to more reliably generate antibody fragments that are active in the cytosol (Cattaneo and Biocca, 1999; Ohage et al., 1999; Wo¨rn and Plu¨ckthun, 2001) . Among these, expression of scFvs in yeast is attractive since it is possible to select from antibody libraries and directly test for binding activity in a eucaryotic system (Visintin et al., 1999; Wo¨rn et al., 2000; De Jaeger et al., 2000; Tse et al., 2002) .
Here we have applied a two-step strategy to isolate intracellular scFv fragments that interact with the cytoplasmic domain of human EGFR. After enrichment of phage-displayed, EGFR-specific antibody fragments from a combinatorial library, a yeast two-hybrid screen was performed to identify scFvs that are functional in the intracellular milieu of eukaryotic cells. Subsequently, interaction of antibody fragments with the intracellular domain of EGFR in vitro and in mammalian cells in vivo was confirmed in GST pull-down and coimmunoprecipitation experiments. Confocal laser scanning microscopy proved that upon cytoplasmic expression in human tumor cells, scFvs colocalize with EGFR at the plasma membrane.
Results
Enrichment of EGFR-specific scFvs from a phage displayed mouse antibody library A scFv antibody library was generated from cDNA derived from the spleens of mice immunized with recombinant human EGFR kinase domain following procedures established previously (Barbas et al., 1991; Andris-Widhopf et al., 2001; Rader and Barbas, 1997) . ScFvs in this library consist of an N-terminal k lightchain variable domain and a C-terminal heavy-chain variable domain, linked by a seven or an 18 amino-acid flexible linker. The initial library was highly diverse, consisting of more than 2 Â 10 8 independent clones. Antibodies binding the EGFR kinase domain were enriched by several rounds of panning against immobilized EGFR antigen. In the third panning round, the ratio of output to input phage started to increase and enhanced binding to EGFR was detected by ELISA, indicating a successful enrichment of EGFR-specific scFvs (Table 1 ). This preselected library was subcloned for yeast two-hybrid screening.
Construction of a yeast library for expression of EGFRspecific scFv fragments
ScFv fragments were isolated from phagemids and inserted into modified pGADT7 yeast two-hybrid prey vector. The resulting plasmids encode fusion proteins consisting of the GAL4 transactivation domain (AD), a sequence tag derived from influenza virus hemagglutinin (HA), and a C-terminal scFv antibody (Figure 1a, upper panel) . A yeast two-hybrid bait vector was constructed by inserting an EGFR cDNA fragment encoding aminoacid residues 645-1186 3 0 of the GAL4 DNA-binding domain (BD) into plasmid pGBKT7 (Figure 1a , lower panel). Saccharomyces cerevisiae AH109 cells were transformed with the resulting pGBKT7-EGFR vector and expression of the GAL4 BD-EGFR fusion protein was verified by immunoblot analysis of yeast lysates using GAL4 BD-and EGFR-specific antibodies (Figure 1b) . Subsequently, yeast cells harboring the bait construct were also transformed with the pGADT7-scFv library. Figure 2a , lower panel). Yeast cells containing EGFR bait and scFv prey vectors, and expressing ADE2 and HIS3 reporter genes were selected on high-stringency selection media lacking tryptophan, leucine, histidine, and adenine. Subsequently, the resulting yeast colonies were replated on the same selection media containing Xa-Gal to test for expression of a-galactosidase (Figure 2b ). A total of 223 blue yeast colonies were obtained. Control cells transformed with pGBKT7-EGFR plasmid and empty pGADT7 vector, or empty pGBKT7 and pGADT7-scFv did not grow on highstringency selection media demonstrating that interaction between bait and prey in the selected yeast clones was specific and dependent on the simultaneous presence of scFv and EGFR protein domains (data not shown).
Molecular analysis of EGFR-specific scFv fragments
Plasmid DNA of 24 randomly chosen, a-galactosidaseexpressing colonies was isolated and upon PCR amplification of scFv inserts, the diversity of selected antibody fragments was analysed by digestion of PCR products with restriction enzyme Mval (Figure 3a) . Based on the resulting restriction patterns, scFvs were subgrouped into five different groups represented by scFv fragments # 2 (group of 13 clones), # 8 (group of seven clones), and # 29 (group of two clones). ScFv clones # 22 and # 30 displayed unique Mval restriction patterns. Reconstitution of functional GAL4 upon coexpression of the individual GAL4 AD-scFv fragments and GAL4 BD-EGFR protein was confirmed for all five clones upon amplification of plasmid DNA in Escherichia coli and retransformation of yeast cells. In contrast, transformation of yeast with pGBKT7-EGFR and a control pGADT7-scFv vector facilitating intracellular expression of Myc-tag-specific scFv(9E10) fused to GAL4 AD did not result in colonies surviving selection ( Figure 2b ). Subsequent analysis of DNA and deduced amino-acid sequences revealed high homology in the framework and complementarity determining regions (CDRs) (Kabat et al., 1991) of the scFvs' heavy and light chains ( Figure 3b and data not shown). The CDRs in the VH region of scFvs 22 and 30 were identical, but VH framework sequences of these clones differed in several amino-acid positions. Interestingly, while the unselected yeast library consisted primarily of scFv plasmids with an 18 amino-acid linker, the majority of selected clones represented by scFvs 2, 8, and 30 contained the short seven amino-acid linker.
Binding of in vitro translated scFv fragments to recombinant EGFR
Interaction of yeast-selected scFv antibody fragments with the cytoplasmic portion of human EGFR was tested in glutathione S transferase (GST) pull-down experiments as a cell-free system. Bacterially expressed GST-EGFR fusion protein containing EGFR aminoacid residues 645-1186, or GST control protein were immobilized on glutathione beads and incubated with in vitro translated, 35 S-labeled scFvs 2, 8, 22, 29, and 30. Upon precipitation of beads, bound proteins were analysed by SDS-PAGE and autoradiography of the gels. As shown in Figure 4a , all scFvs tested displayed specific binding to recombinant GST-EGFR protein but not to GST alone. To further confirm specificity for EGFR, a similar GST pull-down experiment was conducted with 35 S-labeled scFv 2 using a recombinant GST fusion protein containing the intracellular portion of human ErbB2, a tyrosine kinase closely related to EGFR. Whereas binding to GST-EGFR could be verified, no binding of scFv to GST-ErbB2 could be detected (Figure 4b ).
Interaction of scFv fragments with EGFR in the cytoplasm of mammalian cells
To investigate whether scFv fragments selected in yeast are also functional upon cytoplasmic expression in mammalian cells, we performed coimmunoprecipitation experiments. COS-7 cells were cotransfected with plasmids encoding full-length human EGFR and HAtagged scFv fragments. After transfection, cell lysates were incubated with humanized C225 antibody binding to EGFR extracellular domain (Mendelsohn, 1997) and protein G sepharose beads. Upon precipitation, bound proteins were analysed by SDS-PAGE and immunoblotting with anti-HA antibody as shown in Figure 5 . Protein bands migrating at the size expected for scFv fragments were detected in EGFR-immunoprecipitates of cells expressing scFvs 2, 8, 29, and 30, indicating that these antibody fragments are functional and bind to EGFR upon cytoplasmic expression. In contrast, intracellularly expressed Myc-tag-specific control scFv(9E10) did not coprecipitate with EGFR ( Figure 5 , lower panel). Also, in EGFR immunoprecipitates from cells expressing scFv 22 no signal was detected. While this might indicate that this antibody is not functional in mammalian cells, it could also be because of the low level of scFv expression found in these cells (data not shown). In most samples, a second protein band migrating below the scFv fragment was detected. This protein most likely bound nonspecifically to protein G beads since it was also present when cell lysates were precipitated in the absence of anti-EGFR antibody. To investigate activity and localization of scFv fragments upon cytoplasmic expression in human tumor cells overexpressing EGFR, A431 epidermoid carcinoma cells were transiently transfected with plasmids encoding HA-tagged, EGFR-specific antibody fragments scFv 2 and scFv 30. Cells were fixed and permeabilized, and presence and localization of scFvs and EGFR target antigen were analysed by detection with HA-tag-specific and anti-EGFR C225 antibodies, followed by FITC-and Cy5-labeled secondary antibodies and confocal laser scanning microscopy. As expected, strong EGFR staining was detected at the plasma membrane of A431 cells (Figure 6a, d, g ). Whereas intracellularly expressed Myc-tag-specific scFv(9E10) was diffusely distributed throughout the cytosol, and to a lesser extent the nucleus of transfected cells (Figure 6h ), anti-EGFR scFvs 2 and 30 were exclusively localized to the plasma membrane and vesicular structures also detected with anti-EGFR antibody (Figure 6b , e). Overlays of EGFR and scFv specific signals confirmed colocalization of scFvs 2 and 30, but not control scFv(9E10) with EGFR ( Figure 6c , f, i). These results demonstrate that the anti-EGFR scFvs are functional upon cytoplasmic expression in human tumor cells and interact with the intracellular domain of the target receptor in vivo.
Discussion
Single chain antibody fragments specific for growth factor receptors and expressed directly in target cells represent a promising concept to interfere selectively S-labeled antibody fragments. Binding of scFvs to glutathione-coupled beads either carrying GST alone (G) or GST-EGFR (E) was analysed by SDS-PAGE of proteins present in precipitated complexes, followed by autoradiography. scFv input (10%) were included as a control (I). (b) Specificity of scFv interaction with EGFR was confirmed further by conducting GST pulldown assays using GST, GST-EGFR and GST-ErbB2 fusion proteins as indicated. The presence of equivalent amounts of GST fusion proteins on precipitated glutathione-coupled beads was controlled by Coomassie staining of SDS-PAGE gels (lower panel) with the multiple signaling processes associated with these proteins (Gschwind et al., 2001; Yarden and Sliwkowski, 2001 ). Previously we could show that scFvs targeted to the lumen of the ER prevent the transit of EGFR or the related ErbB2 molecule to the cell surface, thereby inactivating the transforming potential of these receptor tyrosine kinases (Beerli et al., 1994b Jannot et al., 1996) . While intramolecular disulfide bridges important for antibody stability are correctly formed during expression in the secretory pathway of cells (Steinberger et al., 2000) , single chain antibodies expressed in the reducing environment of the cytosol are often inactive and have a tendency to aggregate (Cattaneo and Biocca, 1999) . This complicates their application for interference with intracellular target proteins. To overcome this problem and to generate antibody fragments that interact with the intracellular domain of EGFR in the cytosol of mammalian cells, here we have chosen a two-step approach combining classical selection of EGFR-binding scFvs by phage display and biopanning with subsequent screening in a yeast two-hybrid system. Different strategies have been developed to more reliably create or identify intrinsically stable antibody fragments (Wo¨rn and Plu¨ckthun, 2001) . Mutagenesis of scFvs and in vitro selection under reducing conditions resulted in molecules correctly folded in the absence of disulfide bridges (Jermutus et al., 2001 ), a prerequisite for functional cytoplasmic intrabodies (Biocca et al., 1995; Cattaneo and Biocca, 1999) . Grafting of the antibody combining site into stabilized framework sequences (Ohage et al., 1999) and fusion of scFvs to another protein serving as a chaperone (Bach et al., 2001 ) have led to the expression of antigen-binding intrabodies in E. coli and might also be applicable in eukaryotic cells. Expression of scFvs in yeast is an attractive alternative since established methodologies are available that allow screening of diverse libraries. Furthermore, functionality of antibody fragments in the cytoplasm and nucleus of lower eukaryotic cells appears to be predictive for their behavior upon expression in the intracellular milieu of mammalian cells (Visintin et al., 1999; De Jaeger et al., 2000; Wo¨rn et al., 2000; Tse et al., 2002) . After enrichment of phage-displayed, EGFR-specific antibody fragments from a combinatorial library and transfer into a yeast two-hybrid screen, we could isolate a panel of scFvs that are active in the cytosol and bind strongly to the intracellular domain of human EGFR.
In unselected combinatorial libraries antibody fragments that fold correctly in the absence of disulfide bonds and interact with their target antigen in the reducing intracellular environment appear to be very rare. When a mixture of 5 Â 10 5 plasmids from a random scFv library was screened in a yeast two-hybrid system using the coat protein of a plant virus as a model antigen, no functional intrabody could be selected, whereas a scFv fragment previously shown to bind to this target antigen under cytoplasmic conditions and added to the library at a frequency of 1 in 5 Â 10 5 was successfully recovered (Visintin et al., 1999) . Indeed, direct yeast two-hybrid screening of a portion of the unselected anti-EGFR scFv library (approximately 10 5 independent plasmids) did not result in the identification of functional EGFR-specific intrabodies (data not shown). Owing to limitations in transformation efficiency, quantitative transfer of combinatorial scFv libraries of more than approximately 10 6 independent clones into a yeast screening system is not practical (Tse et al., 2002) . Therefore, EGFR-binding antibody fragments in our initial phage display library were enriched by three rounds of biopanning, reducing the complexity of the library to a value below 10 6 , which proved suitable for subsequent expression in yeast. Screening of 1.5 Â 10 5 pGADT7-scFv plasmids yielded 223 a-galactosidase-expressing yeast colonies that represented at least five independent scFv clones.
Interaction of the isolated antibody fragments with the intracellular domain of EGFR in vitro and in mammalian cells in vivo was confirmed in GST pulldown and co-immunoprecipitation experiments. Thereby no crossreactivity of scFvs with the tyrosine kinase domain of the closely related ErbB2 protein was found. Two of the scFv molecules were also tested in colocalization studies in human tumor cells. Upon cytoplasmic expression, the EGFR-specific antibody fragments were found together with EGFR at the plasma membrane, whereas a control scFv was diffusely Figure 5 Binding of intracellular scFv fragments to EGFR in vivo. COS-7 cells were transiently cotransfected with plasmids encoding full-length human EGFR and HA-tagged, EGFR-specific antibody fragments. Interaction of cytoplasmic scFvs with EGFR was tested in coimmunoprecipitation experiments. Cleared cell lysates were incubated with humanized C225 antibody binding EGFR extracellular domain and protein G sepharose beads (+), or protein G sepharose beads in the absence of C225 (À). Upon precipitation of beads, bound proteins were analysed by SDS-PAGE and immunoblotting with rat anti-HA IgG followed by HRP-coupled secondary antibody and chemiluminescent detection. In vitro translated anti-EGFR scFv 30 was included as a control for detection of scFv. Lanes loaded either with C225 antibody, or immunoprecipitate from cells transfected with EGFR plasmid and cDNA encoding Myc-tag-specific scFv(9E10) served as negative controls. An additional protein band not representing scFv but crossreacting with the antibodies used for detection migrates below the EGFR-specific antibody fragments distributed throughout the cytosol and nucleus. We have also investigated possible effects of intrabody expression on EGFR activation. For anti-EGFR scFv(225) that blocks ligand binding to the extracellular domain of the receptor, it was shown that autocrine production of the scFv inhibits EGF-dependent activation and growth of transformed cells (Beerli et al., 1994a . In contrast, in COS-7 cells transiently transfected with constructs encoding human EGFR and cytoplasmic intrabodies specific for the intracellular part of EGFR, no apparent effects on EGFR tyrosine phosphorylation were noted in the presence or absence of EGF (data not shown). This suggests that the scFvs do not directly block sequences crucial for EGFR kinase activity such as the ATP-binding site (Russo et al., 1985) , while it does not rule out the possibility of subtle effects on the interaction of the receptor with individual downstream substrates or adapter proteins.
In the case of p21Ras or phospholipase C-g1, cytoplasmic intrabodies inhibited activity of their target proteins by sequestering them to antibody aggregates with a different subcellular localization and increased proteasomal degradation of the resulting antibodyantigen complexes (Lener et al., 2000; Cardinale et al., 2001; Yi et al., 2001) . Thereby for p21Ras-specific intrabodies to be effective, direct interference with the intrinsic GTPase activity was not required (Lener et al., 2000) . Here confocal laser scanning microscopy showed that in the presence of cytoplasmic scFvs, EGFR remained at its normal location at the plasma membrane. Intrabodies were not sequestered to aggregates but colocalized with the target receptor, making scFvdependent redistribution of EGFR unlikely to occur. However, modification of scFv sequences by introducing intracellular routing and ubiquitination signals might allow to downmodulate EGFR signaling by redirecting the receptor to alternative cellular compartments or enhance its proteasomal degradation (Persic et al., 1997; Cattaneo and Biocca, 1999; Parisien et al., 2001; Kile et al., 2002) .
The scFv plasmid library used for selection in yeast consisted of a mixture of antibody fragments either containing a seven or an 18 amino-acid linker sequence to connect light-and heavy-chain variable domains. Figure 6 Intracellular localization of scFv fragments in A431 cells. EGFR overexpressing A431 tumor cells transiently transfected with plasmids encoding HA-tagged, EGFR-specific antibody fragments scFv 2 (a, b, c) and scFv 30 (d, e, f) were fixed and permeabilized. Cells were stained with EGFR-specific C225 antibody followed by Cy5-labeled secondary antibody (a, d, g), and HAtag-specific antibody followed by FITC-labeled secondary antibody (b, e, h). Localization was analysed by confocal laser scanning microscopy. Cy5 and FITC channels were merged to demonstrate colocalization (c, f, i). Myc-tag-specific scFv(9E10) was included as a control (g, h, i) Intracellular antibodies specific for human EGF receptor S Hyland et al Before yeast selection, the majority of scFvs carried the long linker. However, 21 of 24 anti-EGFR intrabodies individually analysed after selection harbored the short linker, suggesting an enrichment of these clones during yeast two-hybrid screening. Short linker sequences usually prevent proper intramolecular association of a scFv's heavy-and light-chain sequences, but favor noncovalent interaction of VH and VL from two neighboring scFv molecules resulting in a bivalent antibody fragment termed diabody (Holliger et al., 1993) . During screening of scFvs under highly stringent conditions in yeast, bivalent intrabodies interacting more strongly with the target antigen in the cytosol might have had a selective advantage over similar monovalent molecules.
Despite different linker length, the amino-acid sequences of heavy-and light-chain variable domains of the isolated anti-EGFR scFvs were highly homologous. Previously it has been described that functional BCR-ABL-specific intrabodies selected from a library in yeast carried only a limited set of different framework regions, possibly because of their contribution to enhanced intracellular stability and solubility (Tse et al., 2002) . However, while in that case a high degree of diversity was still found in the CDR3 regions that are most important for antigen specificity (Xu and Davis, 2000) , here CDR3 sequences of different independent scFv clones were either identical or differed only in a few amino-acid positions. Therefore, most of the scFvs isolated from yeast might be directed against the same EGFR epitope. This could be because of the preferential enrichment of scFvs recognizing an immunodominant epitope during biopanning of the phage display library, or selection of antibody fragments recognizing a sequence best accessible upon expression of the cytoplasmic domain of EGFR in yeast.
We showed that antibody phage display methodology combined with subsequent selection in a yeast twohybrid system is a suitable strategy to identify EGFRspecific scFv antibodies that are functional upon cytoplasmic expression in tumor cells. Since an appropriate screening system has now been established, starting out from a more diverse, nonimmune phage display library (Tse et al., 2002) , and using for selection a variety of smaller EGFR fragments might allow to isolate scFv intrabodies recognizing additional EGFR epitopes. Our results suggest that similar approaches could also be applicable for the generation of intrabodies targeted to the cytoplasmic domains of other ErbB receptor tyrosine kinases and a wide range of more diverse growth factor receptors.
Materials and methods

Construction of a mouse scFv phage display library
Total RNA was isolated from the spleens of Balb/c mice immunized with purified recombinant human EGFR kinase domain (kindly provided by Dr N Lydon, now Amgen Inc., Thousand Oaks, CA, USA) using Trizol (Invitrogen, Carlsbad, CA, USA). First strand cDNA was prepared from 20 mg of total RNA using AMV Reverse Transcriptase (Invitrogen). Heavy-and light-chain variable domain coding regions were amplified by PCR and linked by overlap extension as described previously (Andris-Widhopf et al., 2001) . The final PCR product encoding a library of scFv antibodies, where heavyand light-chain variable domains are linked either by a seven (GGSSRSS) or an 18 (SSGGGGSGGGGGGSSRSS) aminoacid linker, was digested with the restriction endonuclease Sfil, gel-purified and cloned into Sfil-digested pComb3H phagemid DNA (Barbas et al., 1991; Rader and Barbas, 1997) . The primary library consisted of 2.4 Â 10 8 independent transformants. Phage displaying scFv was produced as described (Barbas et al., 1991 ).
Selection of EGFR-specific scFv antibodies by phage display
Panning was carried out against immobilized antigen in wells of a 96-well plate, using 1 mg of human EGFR kinase domain in 25 ml of TBS for coating. Coated wells were blocked with TBS/3% BSA for 1 h at 371C. In total, 2-3 Â 10 12 PFU of scFvdisplaying phage was then applied per antigen-coated well in 50 ml TBS/1% BSA and incubated for 2 h at 371C. In the first selection round, two wells were used, whereas in the consecutive rounds, only one well was used. Wells were washed five times (first round) or 10 times (second and third round) with TBS/0.1% Tween-20. Bound phage were then eluted with 50 ml Trypsin (10 mg/ml) for 30 min at 371C and used to infect exponentially growing E. coli ER2537 (New England Biolabs, Beverly, MA, USA). Phage was grown and purified from the supernatants of overnight cultures as described (Barbas et al., 1991) .
Construction of an anti-EGFR scFv library for yeast two-hybrid screening
A derivative of pGADT7 yeast two-hybrid prey vector (Clontech, Heidelberg, Germany) suitable for subcloning of scFv antibody fragments was constructed by amplifying a cDNA fragment encoding Myc-tag-specific scFv(9E10) antibody via PCR using plasmid pWW152-9E10 (Altenschmidt et al., 1997) 0 of GAL4 activation domain in the prey vector, resulting in plasmid pGADT7-9E10. pComb3H phagemid DNA containing the preselected anti-EGFR scFv library after the third panning round was digested with Sfil, scFv DNA fragments were isolated and used to replace scFv(9E10) in Sfil-digested pGADT7-9E10. The complexity of the resulting pGADT7-scFv library was 1.5 Â 10 5 .
Yeast two-hybrid screening
For construction of the yeast two-hybrid bait vector, a cDNA fragment encoding the cytoplasmic part of EGFR (amino-acid residues 645-1186) was derived by PCR using human EGFR cDNA as a template and oligonucleotides EGFR 5 0 Smal 5 0 -ggcctcccggggCGAAGGC-GCCAC-3 0 and EGFR 3 0 Sall 5 0 -atactagtcgacgtggTCATGCTCC-3 0 that introduced Smal and Sall restriction sites at the 5 0 and 3 0 ends of the PCR product (EGFR sequences in upper case). The EGFR cDNA fragment was digested with Smal and Sall and inserted into plasmid pGBKT7 (Clontech). The resulting vector pGBKT7-EGFR encodes GAL4 DNA-binding domain fused in frame to the cytoplasmic fragment of human EGFR.
Yeast transformation and two-hybrid screening procedures were carried out according to the manufacturer's recommendations (Matchmaker GAL4 two-hybrid system 3; Clontech). Briefly, competent S. cerevisiae AH109 cells were prepared by the PEG/lithium acetate method and sequentially transformed by heat shock with pGBKT7-EGFR and the anti-EGFR pGADT7-scFv library. Transformants were selected for the presence of both vectors on media lacking leucin and tryptophan. Expression of the bait protein was confirmed by immunoblot analysis of yeast extracts using anti-GAL4 BD IgG (Clontech) or 15E polyclonal anti-EGFR serum (Gullick et al, 1985) . Yeast clones expressing all three reporter genes ADE2, HIS3, and MEL1/lacZ were selected on high-stringency selection media lacking adenine and histidine, and containing X-a-Gal for detection of a-galactosidase activity. pGADT7-scFv plasmids were isolated from single yeast colonies and scFv inserts were amplified by PCR using 3 0 AD and T7 primers (Clontech). ScFv PCR products were digested with Mval and fragments were separated by gel electrophoresis. One prototype pGADT7-scFv plasmid for each group of identical Mval restriction patterns was chosen, and scFv interaction with EGFR was confirmed by retransformation and selection of yeast cells. Subsequently, pGADT7-scFv plasmids containing functionally active antibody fragments were digested with Sfil and scFv cDNAs were inserted into a pcDNA3.1/Zeo (+) vector (Invitrogen, Karlsruhe, Germany) previously modified by including Sfil restriction sites for subcloning and a C-terminal HA-tag for protein detection.
GST pull-down assays
For bacterial expression of a GST-EGFR fusion protein, a cDNA fragment encoding amino-acid residues 645-1186 of human EGFR was amplified by PCR using oligonucleotides EGFR 5 0 Sall/Xhol 5 0 -aaaaaagtcgactcgagCGAAGGCGCCA-CATCGTTC-3 0 and EGFR 3 0 Xbal/Notl 5 0 -aaaaaagcggccgctctagaGCTCCAATAAATTCACTGC-3 0 (EGFR sequences in upper case), and was cloned in frame with GST in the vector pGEX-4T-1 (Amersham Biosciences, Freiburg, Germany). E. coli BL21-CodonPlus (DE3)-RP (Stratagene, Heidelberg, Germany) harboring the resulting pGEX-4T-1-EGFR vector were induced with 1 mm IPTG at an OD600 of 0.8 and grown overnight at 201C. Bacterial cell lysates were prepared by sonication in PBS containing 0.5 mm PMSF, 1 mm EDTA, 1% Triton X-100, and were cleared by centrifugation. Cleared lysates were incubated with glutathione sepharose beads (Amersham Biosciences) for 1 h at 41C, and beads were subsequently washed four times with PBS. Binding reactions typically contained 1 mg of recombinant GST-EGFR fusion protein or 10 mg GST protein as a negative control immobilized on glutathione sepharose beads. In vitro translation of scFv antibody fragments was carried out with the T7 promoter containing pGADT7-scFv plasmids using the TNT T7 Quick Coupled Transcription/Translation System (Promega, Mannheim, Germany) in the presence of 35 S-labeled methionine according to the manufacturer's recommendations, in vitro translated scFv fragments were added to GST-EGFR or GST bound to glutathione sepharose beads in 1.3 ml binding buffer containing 50 mm Tris-HCl pH 8.0, 100 mm NaCl, 10 mm MgCl 2 , 10% glycerol, 0.1% NP-40, 0.3 mm DTT, 1 mm EDTA and complete EDTA-free protease inhibitor mix according to the manufacturer's recommendation (Roche Diagnostics, Mannheim, Germany). Samples were incubated with gentle inversion for 2 h at 41C, followed by three washing steps with binding buffer. Washed beads were resuspended in 25 ml of 5 Â SDS loading buffer, boiled, and liberated proteins were analysed by SDS-PAGE.
Maintenance of cells and transfection procedures
COS-7 SV40-transformed African green monkey kidney cells and A431 human epidermoid tumor cells were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS), 2 mm l-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin. For analysis of interaction of scFv antibody fragments with human EGFR in vivo, COS-7 cells were transiently cotransfected with full-length EGFR encoding plasmid pLTR-EGFR (Hills et al., 1995) (kindly provided by Dr WJ Gullick, University of Kent at Canterbury, Canterbury, UK), and pcDNA3.1/Zeo (+) vectors encoding HA-tagged anti-EGFR scFvs or Myc-tag-specific scFv(9E10) as a control. As a transfection reagent in all experiments Fugene 6 (Roche Diagnostics) was used according to the manufacturer's recommendations.
Coimmunoprecipitation and immunofluorescence staining
At 48 h after transfection, COS-7 cells were lysed in 2 ml of icecold lysis buffer containing 1% Triton X-100, 50 mm Tris pH 7.5, 150 mm NaCl, 5 mm EGTA, and complete EDTA-free protease inhibitor mix. Following 30 min incubation on ice, lysates were cleared by centrifugation and proteins binding unspecifically to protein G sepharose were removed by incubation of 900 ml cleared lysates for 3 h at 41C with 50 ml of a 50% slurry of protein G sepharose beads (Amersham Biosciences). After separation from the beads by centrifugation, supernatant was collected and incubated for 1 h at 41C with 2 mg of monoclonal C225 humanized anti-EGFR IgG (kindly provided by Dr J Mendelsohn, MD Anderson Cancer Center, Houston, TX, USA) followed by addition of 50 ml of protein G sepharose beads and gentle rotation for 3 h at 41C. Beads were collected by centrifugation and washed three times using lysis buffer. Bound proteins were eluted in 50 ml of SDS loading buffer and analysed by SDS-PAGE and immunoblotting with rat anti-HA tag antibody followed by horseradish peroxidase-conjugated goat anti-rat IgG and chemiluminescent detection.
Intracellular localization of scFv antibody fragments was analysed in A431 cells transiently transfected with pcDNA3.1/ Zeo-scFv constructs. Transfected cells were grown on coverslips and 48 h after transfection were fixed with 3% paraformaldehyde for 10 min at room temperature, followed by permeabilization with 0.1% Triton X-100 in PBS for 5 min. Cells were washed with PBS and incubated for 1 h with primary antibodies C225 anti-EGFR and rat anti-HA tag (Roche Diagnostics) in PBS containing 3% BSA, after intensive washing followed by incubation with Cy-5 and FITC-labeled Alexa Fluor TM 633 goat anti-human IgG and Alexa Fluor TM 488 goat anti-rat IgG (Molecular Probes, Eugene, OR, USA). Then samples were analysed using a Leica TCS SL laser scanning microscope (Leica Mikrosysteme, Bensheim, Germany). 
